NEW YORK – At the recent American Society of Clinical Oncology's virtual annual meeting, Andrés Poveda shared results from the Phase III SOLO-2 clinical trial of olaparib (AstraZeneca/Merck's Lynparza) maintenance therapy for women with chemotherapy-sensitive, relapsed ovarian cancer and pathogenic BRCA1/2 mutations — a patient group that had an average survival benefit of more than a year on the PARP inhibitor.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.